BioNxt Solutions (TSE:BNXT) has released an update.
BioNxt Solutions Inc. has received a positive international examination report from the European Patent Office for its patent application on a sublingual drug delivery system for anticancer drugs targeting neurodegenerative diseases, including MS and MG. The company anticipates EU patent grant within two months and plans to extend its patent filings globally, potentially offering protection until 2045. BioNxt is progressing in its development of an orally dispersible Cladribine dosage form, targeting the expanding MS drug market projected to reach USD 41 billion by 2033.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.
